Vaccine makers split on protection against omicron variant
Cambridge, Massachusetts/London | Two of the three biggest Western vaccine makers tried to calm fears over a new coronavirus strain, with the University of Oxford and BioNTech predicting existing jabs would continue to prevent severe disease.
Markets had fallen earlier on Tuesday after the chief executive of Moderna, the third big vaccine maker, told the Financial Times that existing vaccines were likely to be much less effective against the omicron variant, and it would take months to manufacture replacement jabs at scale.
Financial Times
Subscribe to gift this article
Gift 5 articles to anyone you choose each month when you subscribe.
Subscribe nowAlready a subscriber?
Introducing your Newsfeed
Follow the topics, people and companies that matter to you.
Find out moreRead More
Latest In Healthcare & fitness
Fetching latest articles